Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca
RedHill to promote Movantik ® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia ® and Aemcolo ® Movantik ® generated U.S. net sales of $96 million in 2019 TEL-AVIV, Israel and RALEIGH, N.C. ...
View HTML
Toggle Summary RedHill Biopharma Provides Business Update
TEL-AVIV, Israel and RALEIGH, N.C. , March 25, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today provided a business update on proactive measures being taken with regard to ...
View HTML
Toggle Summary RedHill Biopharma Announces Preferred Position for Talicia® on Express Scripts National Preferred Formulary Effective March 13, 2020
RedHill recently launched Talicia ® in the U.S. , calling on gastroenterologists, primary care physicians and other healthcare providers --- Talicia ® is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to address the high ...
View HTML
Toggle Summary RedHill Biopharma Provides Update on Opaganib (Yeliva®)
       Phase 2 study evaluating RedHill’s proprietary NCE 1 opaganib (Yeliva ® , ABC294640) in prostate cancer initiated at Medical University of South Carolina , supported by an NCI grant ---        Recruitment initiated in second arm of Phase 1/2a study evaluating opaganib in combination with ...
View HTML
Toggle Summary RedHill Biopharma to Present at the Barclays Global Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , March 10, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that Mr. Dror Ben-Asher , RedHill’s Chief Executive Officer, will ...
View HTML
Toggle Summary RedHill Biopharma Announces U.S. Commercial Launch of Talicia® for H. pylori Infection
Talicia ® is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to address the high and growing H. pylori resistance to clarithromycin -- Talicia ® is targeting an estimated two million U.S. patients treated annually for H. ...
View HTML
Toggle Summary RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights
Key Highlights: Talicia ®  approved by the FDA for the treatment of H. pylori infection in adults; U.S. launch with RedHill’s sales force expected by mid-March 2020   Acquisition of global rights to Movantik ® (naloxegol) for the treatment of opioid-induced constipation (OIC) in adults from ...
View HTML
Toggle Summary RedHill Biopharma to Host Full-Year 2019 Financial Results Conference Call on March 4, 2020
TEL-AVIV, Israel and RALEIGH, N.C. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal ...
View HTML
Toggle Summary RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca
RedHill to promote Movantik ® in the U.S. upon closing  Movantik ® generated U.S. net sales of $96 million in 2019 Acquisition financing to be provided by HealthCare Royalty Partners (HCR) as part of the $115 million non-dilutive financing    TEL-AVIV, Israel and RALEIGH, N.C. , Feb. ...
View HTML
Toggle Summary RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners
RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia ® this quarter and the ongoing promotion of Aemcolo ® RedHill will receive an additional $50 million to fund the acquisition of rights to Movantik ® from AstraZeneca ...
View HTML